UROSEPSIS - Detailed Clinical Note

Incorporating SSC 2026, EAU 2026, IDSA 2025, and Latest Evidence-Based Guidelines

1. DEFINITION AND OVERVIEW

• Sepsis: Life-threatening organ dysfunction caused by a dysregulated host response to infection originating from the urinary tract, demonstrated by an acute SOFA score increase of ≥2 points from baseline.
• Septic Shock: A subset of urosepsis where underlying circulatory, cellular, and metabolic abnormalities are severe enough to substantially increase mortality - defined by vasopressor requirement to maintain MAP ≥65 mmHg AND serum lactate >2 mmol/L (>18 mg/dL) despite adequate volume resuscitation.
• Quick SOFA (qSOFA) - Bedside screening tool (2 of 3 criteria): Respiratory rate ≥22/min + Altered mentation (GCS <15) + Systolic BP ≤100 mmHg.

2. PATHOPHYSIOLOGY

2.1 Microbial Triggers

• Complicated UTI (obstruction, instrumentation, anatomical abnormality)
• Pyelonephritis (especially obstructive)
• Prostate infections / acute bacterial prostatitis
• Post-urological procedures (TURP, ureteroscopy, percutaneous nephrolithotomy, prostate biopsy - 1% risk)

2.2 Microbiology

2.3 Pathogenic Cascade

1. Bacterial invasion of kidney/urinary tract
2. Hematogenous spread / endotoxin (LPS) release
3. Pattern recognition via TLR-4 → NF-kB activation → cytokine storm (TNF-α, IL-1β, IL-6)
4. Endothelial injury → capillary leak → hypovolemia
5. Nitric oxide and prostacyclin-mediated vasodilation → distributive shock
6. Coagulopathy (tissue factor activation, DIC)
7. Mitochondrial dysfunction, cellular apoptosis
8. Multi-organ failure (ARDS, AKI, hepatic dysfunction, encephalopathy)

3. RISK FACTORS AND PREDISPOSING CONDITIONS

• Female sex (uncomplicated UTI), elderly age
• Diabetes mellitus (most common in obstructive AOP)
• Immunocompromise (transplant, HIV, steroids, malignancy)
• Pregnancy
• Neurogenic bladder, functional urinary obstruction

• Urolithiasis with obstruction (impacted ureteric stone - a urological emergency)
• BPH / bladder outlet obstruction
• Anatomical anomalies (horseshoe kidney, duplex systems)
• Urinary catheter (CAUTI is the most common source of MDR gram-negative bacteremia in ICUs)

• Post-ureteroscopy/PCNL/TURP
• Prostate biopsy (urosepsis in ~1% of cases)
• Indwelling stent

4. CLINICAL MANIFESTATIONS

• Fever (>38°C) or hypothermia (<36°C) - hypothermia is an ominous sign
• Rigors / chills
• Flank pain, costovertebral angle tenderness
• Dysuria, frequency, urgency (may be absent in obstructive uropathy)
• Hypotension, tachycardia
• Altered mental status (especially in elderly - may be the only presentation)
• Lethargy, confusion, reduced urine output

• Systolic BP <90 or MAP <65 mmHg
• Lactate >2 mmol/L
• Mottling, prolonged capillary refill
• Oliguria (<0.5 mL/kg/hr for >2 hours)
• Acute confusion or reduced consciousness
• Thrombocytopenia, hypoalbuminemia (predictors of septic shock in obstructive pyelonephritis - PMID 41597508)

Textbook Note: "Patients who present with urosepsis typically have complicated UTI rather than nonobstructive pyelonephritis. Urosepsis can present with or progress to septic shock, which requires life-supporting treatment in addition to antibiotics." - Goldman-Cecil Medicine, 26th Ed.

5. DIAGNOSIS

5.1 Clinical Diagnosis Frameworks

5.2 Laboratory Investigations

• Urine culture + microscopy - obtain before antibiotics; midstream or catheter specimen; pyuria + bacteriuria support diagnosis
• Blood cultures x2 (from different sites, before antibiotics) - SSC 2026 recommends obtaining cultures before antibiotics but not delaying therapy >45 minutes for culture collection
• Serum lactate - ≥2 mmol/L = hypoperfusion marker; ≥4 mmol/L = high-risk; re-check at 2-4 hours if initially elevated
• FBC: WBC >12,000 or <4,000/mm³; thrombocytopenia is a predictor of shock
• CRP, Procalcitonin (PCT): PCT >1.12 µg/L is a predictor of septic shock in obstructive AOP (PMID 41597508); PCT also guides de-escalation (SSC 2026 - see treatment section)
• Renal function, electrolytes, BUN, creatinine - baseline AKI assessment
• LFTs, bilirubin - hepatic dysfunction assessment (SOFA)
• Coagulation screen (INR, APTT, platelets, D-dimer) - DIC evaluation
• ABG - metabolic acidosis (lactate), oxygenation
• Presepsin - emerging biomarker; elevated in AOP; alongside NLR ≥8.7 predicts shock (PMID 41597508)

• Gram stain of urine - rapid identification
• Blood glucose (hyperglycemia common; target <180 mg/dL per SSC 2026)
• Serum albumin (hypoalbuminemia = predictor of septic shock)
• Troponin / BNP if cardiac involvement suspected

5.3 Imaging

CT of abdomen/pelvis should be performed urgently in all patients with urosepsis to identify obstructing calculi, perinephric abscess, emphysematous pyelonephritis, or other surgically correctable pathology.

6. MANAGEMENT

6.1 Time-Critical Bundle Approach (SSC 2026)

1. Measure lactate; re-measure if >2 mmol/L
2. Obtain blood cultures before antibiotic administration
3. Administer broad-spectrum antibiotics
4. Begin 30 mL/kg crystalloid IV for hypotension or lactate ≥4 mmol/L
5. Apply vasopressors if patient is hypotensive during/after fluid resuscitation to maintain MAP ≥65 mmHg

6.2 Resuscitation (SSC 2026)

Fluid Therapy

• Initial fluid resuscitation: SSC 2026 suggests at least 30 mL/kg IV crystalloid within first 3 hours for sepsis-induced hypoperfusion or septic shock (conditional, low certainty)
  • Weight-based calculation on actual body weight; use adjusted/ideal body weight if BMI >30 kg/m²
  • Perform frequent ongoing reassessment - avoid over- and under-resuscitation
• Fluid choice: Balanced crystalloids (Ringer's lactate, Plasmalyte) over normal saline (NS) - NS associated with hyperchloremic acidosis; albumin can be used if substantial crystalloid volumes required
• Fluid removal: New SSC 2026 statement - suggest active fluid removal (i.e., diuresis-guided de-resuscitation) once patient is hemodynamically stable

Vasopressors

• First-line: Norepinephrine (noradrenaline) - start at 3-5 µg/min, titrate to MAP target
• MAP target (SSC 2026 - updated):
  • Standard target: MAP ≥65 mmHg (strong recommendation)
  • New 2026 statement: For older adults (>75 years), a lower MAP target (e.g., 60-65 mmHg) is acceptable (conditional recommendation) - reflecting evidence that higher targets may not improve outcomes in elderly
• Vasopressin: Add as second agent at 0.03 units/min if norepinephrine dose escalating (helps reduce norepinephrine requirements)
• Epinephrine: Third-line agent
• Dopamine: Not recommended as vasopressor in septic shock (increased arrhythmia risk); may be used for bradycardia
• Angiotensin II: Conditional recommendation - may be used as vasopressor in refractory septic shock
• Phenylephrine: Avoid except when norepinephrine causes arrhythmias

Oxygen and Ventilation

• Supplemental oxygen to maintain SpO₂ ≥94%
• ARDS protocol if needed: low tidal volume 6 mL/kg IBW, plateau pressure <30 cmH₂O, PEEP strategies

6.3 Antimicrobial Therapy (SSC 2026 + IDSA 2025 + EAU 2026)

Timing (SSC 2026 - 2026 Updated Statements)

Antibiotic Selection (IDSA 2025 cUTI Guidelines + EAU 2026)

1. Step 1: Risk factors for MDR organisms (prior MDR infection, prior antibiotic exposure, recent hospitalization, long-term care facility, urinary catheter, immunocompromise)
2. Step 2: Local antibiogram (use if local, recent, and relevant - conditional recommendation, IDSA 2025)
3. Step 3: Patient-specific considerations (allergy, contraindications, drug interactions, AKI)
4. Step 4: Antibiotic stewardship (narrowest effective spectrum; de-escalate on culture results)

Duration of Therapy (SSC 2026 + IDSA 2025)

• SSC 2026: Suggests shorter over longer duration of antimicrobial therapy for sepsis/septic shock with adequate source control (conditional, very low certainty)
• Typical duration for urosepsis:
  • Uncomplicated bacteremic pyelonephritis after source control: 7-14 days total (oral step-down after 24-48h clinical improvement)
  • Goldman-Cecil: 5-7 days adequate for ciprofloxacin/levofloxacin in pyelonephritis
  • Septic shock / bacteremia with complications: 14 days (individualize)
  • IDSA 2025: No universal recommendation for optimal duration - use clinical judgment + PCT guidance
• Step-down to oral therapy when: clinically improved, tolerating PO, sensitive organism confirmed, gastrointestinal absorption intact - typically 24-48 hours (trimethoprim-sulfamethoxazole, cefixime, or ciprofloxacin - NOT nitrofurantoin or fosfomycin for pyelonephritis/sepsis)

De-escalation and Stewardship (SSC 2026)

• Review antibiotic therapy daily for de-escalation opportunity once cultures and sensitivities available
• SSC 2026 (new 2026 statement): Suggest using PCT AND clinical evaluation to decide when to discontinue antimicrobial therapy (conditional, low certainty)
• Narrow to the most specific, narrowest-spectrum agent
• Stop antibiotics if sepsis diagnosis is not confirmed and clinical evaluation is reassuring

6.4 Source Control (SSC 2026 + EAU 2026)

Source Control Options in Urosepsis

Key Point: Obstruction-related urosepsis (pyonephrosis, obstructed kidney) MUST be decompressed urgently. Antibiotics alone are insufficient. The obstructed, infected collecting system acts as a reservoir that is inaccessible to antibiotics until drained.

6.5 Corticosteroids (SSC 2026)

• Indication: Septic shock that is unresponsive to adequate fluid resuscitation and vasopressors (refractory shock)
• Regimen: IV hydrocortisone 200 mg/day (continuous infusion preferred over bolus dosing)
• SSC 2026 (maintained from 2021): No additional benefit from doses above 200 mg/day (no benefit at 260 mg/day)
• Do NOT use: Vitamin C IV, IV immunoglobulins, blood purification/hemoperfusion with Polymyxin B (maintained SSC 2026 positions)
• Taper steroids when vasopressors no longer required

6.6 Glucose Management (SSC 2026)

• Start insulin therapy when blood glucose ≥180 mg/dL (10 mmol/L) on two consecutive measurements
• Target glucose range: 144-180 mg/dL (8-10 mmol/L) - avoid hypoglycemia
• Use validated insulin protocols; frequent monitoring

6.7 VTE Prophylaxis (SSC 2026)

• LMWH over unfractionated heparin (UFH) for VTE prophylaxis (maintained 2026)
• Mechanical prophylaxis (compression stockings) when pharmacological prophylaxis is contraindicated

6.8 Renal Replacement Therapy (SSC 2026)

• RRT only for accepted renal indications (refractory acidosis, hyperkalemia, uremic complications, fluid overload refractory to diuretics)
• SSC 2026: Do NOT initiate RRT purely on AKI staging without definitive indication
• Bicarbonate therapy: Only if pH ≤7.20 with AKI Stage 2-3 (AKIN 2-3)

6.9 Blood Transfusion (SSC 2026)

• Restrictive transfusion strategy - transfuse when Hgb <7 g/dL (Hct <21%)
• Hgb target 7-9 g/dL; no benefit to higher targets in most patients
• Exception: Active coronary ischemia, significant ongoing hemorrhage

6.10 ICU / Monitoring Considerations

• ICU admission mandatory for septic shock, refractory hypotension, respiratory failure, multi-organ dysfunction, or high-risk patients
• Continuous monitoring: HR, BP (arterial line preferred), SpO2, urine output, CVP/IVC ultrasound
• POCUS (Point-of-Care Ultrasound): SSC 2026 pediatric guidelines include conditional recommendation for POCUS guidance; adult guidelines support bedside echocardiography for hemodynamic assessment
• Goldman-Cecil: Consider pulmonary artery catheter or echocardiogram especially if known cardiovascular disease

7. BIOMARKERS IN UROSEPSIS

8. ANTIBIOTIC STEWARDSHIP IN UROSEPSIS (EAU 2026)

1. Empiric therapy: Use restricted choice based on local antibiogram; include only necessary spectrum
2. IV-to-oral switch (IVOST): Transition to oral antibiotics within 24-48 hours of clinical stabilization and confirmed susceptibility
3. De-escalation: Narrow spectrum as soon as cultures available - associated with 56% RRR in mortality (EAU 2026)
4. Therapeutic drug monitoring (TDM): For aminoglycosides, vancomycin, and other agents with narrow therapeutic index
5. Bedside consultation: Infectious disease / clinical pharmacist input improves outcomes
6. Duration targets: Shortest effective course; PCT-guided discontinuation (SSC 2026)

9. SPECIAL POPULATIONS

9.1 Elderly Patients (SSC 2026 - New 2026 Statement)

• Lower MAP target acceptable (60-65 mmHg instead of 65 mmHg) - conditional recommendation
• High risk of atypical presentation (confusion, falls, absence of fever/dysuria)
• Higher MDR organism risk

9.2 Obstructive Urosepsis

• MUST undergo emergency source control (PCN or DJ stenting)
• CT abdomen/pelvis mandatory
• Higher ESBL/MDR rates
• Carbapenem empiric therapy often appropriate

9.3 Post-Urological Procedure Sepsis

• High risk organisms including ESBL producers, Enterococci, Pseudomonas
• Broader empiric coverage required
• Review local ecology/antibiogram
• 2025 EAU guidelines: Intra-high pressure renal pelvis during ureteroscopy increases risk - manage with adequate drainage post-procedure

9.4 Renal Transplant Recipients

• Post-hoc analysis (PMID 40489015, 2025): Antibiotic practices significantly associated with treatment outcomes in kidney transplant recipients with urosepsis - individualized, culture-guided therapy is essential
• Immunosuppression blunts inflammatory response - presentation may be subtle

9.5 Candida Urosepsis

• EAU 2026: New dedicated chapter on fungal UTI
• Fluconazole for susceptible Candida in stable patients
• Echinocandin (caspofungin/micafungin) for septic shock, azole-resistant species, or C. glabrata/krusei
• Remove/replace urinary catheter
• SSC 2026: Antifungal coverage suggested in sepsis with risk factors for invasive fungal infection (conditional recommendation)

10. COMPLICATIONS

11. PROGNOSIS

• Mortality without septic shock: 5-10%
• Mortality with septic shock: 20-40%
• Predictors of poor outcome (PMID 41597508 - Systematic Review 2026):
  • Thrombocytopenia
  • Hypoalbuminemia
  • Procalcitonin >1.12 µg/L
  • Presepsin elevation
  • NLR ≥8.7
  • Delay in source control
  • ESBL/MDR pathogen
  • Multi-organ involvement at presentation

12. POST-SEPSIS CARE (SSC 2026 - NEW 2026 SECTION)

1. Primary care clinicians should be competent to support sepsis survivors
2. Post-discharge support strategies should be implemented
3. Evaluation of physical, cognitive, and emotional sequelae post-sepsis is mandatory
4. Medication review at discharge: Conditional recommendation to perform a complete medication review at discharge - avoid polypharmacy from drugs started during acute illness (sedatives, antacids, antipsychotics) that may not be needed after recovery
5. Screen for new/worsened functional limitations, PTSD, anxiety, depression, cognitive impairment

13. GUIDELINE SUMMARY TABLE

REFERENCES

1. Surviving Sepsis Campaign 2026: Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. DOI: 10.1097/CCM.0000000000007075. Published March 23, 2026. (IDSA page)
2. EAU Guidelines on Urological Infections 2026: Bonkat G, Kranz J, Cai T, et al. EAU Guidelines on Urological Infections. European Association of Urology, April 2026. Updated March 2026. (EAU PDF)
3. IDSA 2025 Complicated UTI Guidelines: Infectious Diseases Society of America. IDSA 2025 Guideline Update on Complicated Urinary Tract Infections. (IDSA page)
4. Goldman-Cecil Medicine, 26th Ed. Chapter 263 - Urinary Tract Infections; Chapter 94 - Sepsis and Septic Shock.
5. Harrison's Principles of Internal Medicine, 22nd Ed. (2025) - Sepsis and Septic Shock.
6. Chibu MC et al. (2026). Clinical Characteristics, Microbiological Spectrum, Biomarkers, and Imaging Insights in Acute Pyelonephritis and Its Complicated Forms - A Systematic Review. Medicina (Kaunas). PMID: 41597508.
7. Rozenblat D et al. (2025). Impact of aminoglycosides on survival rate and renal outcomes in patients with urosepsis: a multicenter retrospective study. Ann Intensive Care. PMID: 40216650.
8. Vallee M et al. (2026). Preoperative urine culture in urology: Indications and management - The 2026 French guidelines. Fr J Urol. PMID: 42061511.
9. Krolicki T et al. (2025). Antibiotic practices in kidney transplant recipients with urosepsis are associated with treatment outcomes. Eur J Clin Microbiol Infect Dis. PMID: 40489015.